Strategic ophthalmology research collaboration
We are pleased to have assisted Beta Therapeutics Pty Ltd (Beta Therapeutics) on its recently concluded strategic research collaboration agreement with Oxurion NV (Oxurion).
We’re particularly pleased to be involved on this cross-border collaboration between two companies – one based in Canberra, Australia and the other in Leuven, Belgium – both working together to develop ophthalmological products that will be of benefit worldwide.
Beta Therapeutics is an Australian biotechnology company developing novel heparanase inhibitors. It was co-founded by Dr. Keats Nelms, Professor Chris Parish and Associate Professor Charmaine Simeonovic, all of the Australian National University.
Oxurion is a biopharmaceutical company developing treatments to preserve vision for patients with diseases affecting the back of the eye. Oxurion is listed on Euronext Brussels.
Read more about Beta Therapeutics here.
Read more about Oxurion here.
Read more about Beta Therapeutics’ and Oxurion’s strategic research collaboration here.
fsLAW is proud to have played a small part in Beta Therapeutic’s first steps to develop its novel heparanase inhibitor technology and we look forward to assisting Beta Therapeutics as it grows its business.
Read more about our lawyers’ biotech, cross-border and fundraising experience.
You may also be interested in our work with DotBio on its Series Seed fundraising.
Get in touch to explore how we may help you commercialise your technology.